Modulating T cell functions does not alleviate chronic inflammatory skin lesions in K5.TGFβ1 transgenic mice

Experimental Dermatology

Volumn 19, Issue 5, 2010, Pages 406-415

  Michaelis, Kai ^a   Wallbrecht, Katrin ^a,b   Kerstan, Andreas ^c   Beyersdorf, Niklas ^c   Williams, Cortny ^d   Kerkau, Thomas ^c   Wang, Xiao Jing ^d   Hünig, Thomas ^c   Schön, Michael P ^a,b  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d UNIVERSITY OF COLORADO   (United States)

Author keywords

Costimulation; Inflammation; Psoriasis regulatory T cells; Skin; T cells; TGF ; Transgenic mice

Indexed keywords

CYTOKERATIN 5; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA1;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW TRANSPLANTATION; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL EXPANSION; CONTROLLED STUDY; DISEASE COURSE; FEMALE; IMMUNOCOMPETENT CELL; IMMUNOPATHOGENESIS; IN VIVO STUDY; INNATE IMMUNITY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE FUNCTION; MALE; MOUSE; NONHUMAN; OUTBRED STRAIN; PHENOTYPE; PROTEIN EXPRESSION; PSORIASIS; REGULATORY T LYMPHOCYTE; SKIN INFLAMMATION; T CELL DEPLETION; T LYMPHOCYTE; TRANSGENIC MOUSE; WILD TYPE;

EID: 77953160089     PISSN: 09066705     EISSN: 16000625     Source Type: Journal    
DOI: 10.1111/j.1600-0625.2009.01031.x     Document Type: Article

References (60)

1. Bowcock A M, Krueger J G. Getting under the skin: the immunogenetics of psoriasis. Nat Rev Immunol 2005, 5:699-711.
2. Griffiths C E, Barker J N. Pathogenesis and clinical features of psoriasis. Lancet 2007, 370:263-271.
3. Kupper T S, Fuhlbrigge R C. Immune surveillance in the skin: mechanisms and clinical consequences. Nat Rev Immunol 2004, 4:211-222.
4. Lowes M A, Bowcock A M, Krueger J G. Pathogenesis and therapy of psoriasis. Nature 2007, 445:866-873.
5. Schön M P, Boehncke W H. Psoriasis. N Engl J Med 2005, 352:1899-1912.
6. Gudjonsson J E, Johnston A, Dyson M, Valdimarsson H, Elder J T. Mouse models of psoriasis. J Invest Dermatol 2007, 127:1292-1308.
7. Schön M P. Animal models of psoriasis - a critical appraisal. Exp Dermatol 2008, 17:703-712.
8. Li A G, Wang D, Feng X H, Wang X J. Latent TGFbeta1 overexpression in keratinocytes results in a severe psoriasis-like skin disorder. EMBO J 2004, 23:1770-1781.
9. Flisiak I, Chodynicka B, Porebski P, Flisiak R. Association between psoriasis severity and transforming growth factor beta (1) and beta (2) in plasma and scales from psoriatic lesions. Cytokine 2002, 19:121-125.
10. Pauls K, Schön M, Kubitza R C. Role of integrin alphaE(CD103)beta7 for tissue-specific epidermal localization of CD8 + T lymphocytes. J Invest Dermatol 2001, 117:569-575.
11. Cai J P, Falanga V, Taylor J R, Chin Y H. Transforming growth factor-beta differentially regulates the adhesiveness of normal and psoriatic dermal microvascular endothelial cells for peripheral blood mononuclear cells. J Invest Dermatol 1992, 98:405-409.
12. Carducci M, Mussi A, Bonifati C. Effect of data normalization for age on the correlations between corneometric values and serum molecule levels in plaque-type psoriatic patients. Acta Derm Venereol 1997, 77:110-114.
13. Flisiak I, Porebski P, Flisiak R, Chodynicka B. Plasma transforming growth factor beta1 as a biomarker of psoriasis activity and treatment efficacy. Biomarkers 2003, 8:437-443.
14. Nockowski P, Szepietowski J C, Ziarkiewicz M, Baran E. Serum concentrations of transforming growth factor beta 1 in patients with psoriasis vulgaris. Acta Dermatovenerol Croat 2004, 12:2-6.
15. Gorelik L, Flavell R A. Transforming growth factor-beta in T-cell biology. Nat Rev Immunol 2002, 2:46-53.
16. Rubtsov Y P, Rudensky A Y. TGFbeta signalling in control of T-cell-mediated self-reactivity. Nat Rev Immunol 2007, 7:443-453.
17. Veldhoen M, Stockinger B. TGFbeta1, a " Jack of all trades": the link with pro-inflammatory IL-17-producing T cells. Trends Immunol 2006, 27:358-361.
18. Wan Y Y, Flavell R A. 'Yin-Yang' functions of transforming growth factor-beta and T regulatory cells in immune regulation. Immunol Rev 2007, 220:199-213.
19. Bettelli E, Carrier Y, Gao W. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006, 441:235-238.
20. Harrington L E, Mangan P R, Weaver C T. Expanding the effector CD4 T-cell repertoire: the Th17 lineage. Curr Opin Immunol 2006, 18:349-356.
21. Weaver C T, Harrington L E, Mangan P R, Gavrieli M, Murphy K M. Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity 2006, 24:677-688.
22. Brownell I. Sexy and 17: TH17 effector T cells and psoriasis. J Drugs Dermatol 2007, 6:853-856.
23. Lowes M A, Kikuchi T, Fuentes-Duculan J. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol 2008, 128:1207-1211.
24. Sabat R, Philipp S, Hoflich C. Immunopathogenesis of psoriasis. Exp Dermatol 2007, 16:779-798.
25. Li M O, Flavell R A. Contextual regulation of inflammation: a duet by transforming growth factor-beta and interleukin-10. Immunity 2008, 28:468-476.
26. Fontenot J D, Gavin M A, Rudensky A Y. Foxp3 programs the development and function of CD4 + CD25 + regulatory T cells. Nat Immunol 2003, 4:330-336.
27. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003, 299:1057-1061.
28. Hori S, Sakaguchi S. Foxp3: a critical regulator of the development and function of regulatory T cells. Microbes Infect 2004, 6:745-751.
29. Zheng Y, Rudensky A Y. Foxp3 in control of the regulatory T cell lineage. Nat Immunol 2007, 8:457-462.
30. Collison L W, Workman C J, Kuo T T. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 2007, 450:566-569.
31. Pandiyan P, Zheng L, Ishihara S, Reed J, Lenardo M J. CD4 + CD25 + Foxp3 + regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4 + T cells. Nat Immunol 2007, 8:1353-1362.
32. Scheffold A, Murphy K M, Hofer T. Competition for cytokines: T(reg) cells take all. Nat Immunol 2007, 8:1285-1287.
33. Dennehy K M, Elias F, Zeder-Lutz G. Cutting edge: monovalency of CD28 maintains the antigen dependence of T cell costimulatory responses. J Immunol 2006, 176:5725-5729.
34. Hünig T. Manipulation of regulatory T-cell number and function with CD28-specific monoclonal antibodies. Adv Immunol 2007, 95:111-148.
35. Kess D, Peters T, Zamek J. CD4 + T cell-associated pathophysiology critically depends on CD18 gene dose effects in a murine model of psoriasis. J Immunol 2003, 171:5697-5706.
36. Nicolas J F, Chamchick N, Thivolet J, Wijdenes J, Morel P, Revillard J P. CD4 antibody treatment of severe psoriasis. Lancet 1991, 338:321.
37. Prinz J, Braun-Falco O, Meurer M. Chimaeric CD4 monoclonal antibody in treatment of generalised pustular psoriasis. Lancet 1991, 338:320-321.
38. Han G, Williams CA, Salter K, Garl PJ, Li AG, Wang XJ. A role for TGFbeta signaling in the pathogenesis of psoriasis. J Invest Dermatol 2009, PMID: 19710682
39. Byrne C, Fuchs E. Probing keratinocyte and differentiation specificity of the human K5 promoter in vitro and in transgenic mice. Mol Cell Biol 1993, 13:3176-3190.
40. Casatorres J, Navarro J M, Blessing M, Jorcano J L. Analysis of the control of expression and tissue specificity of the keratin 5 gene, characteristic of basal keratinocytes. Fundamental role of an AP-1 element. J Biol Chem 1994, 269:20489-20496.
41. Lomada D, Liu B, Coghlan L, Hu Y, Richie E R. Thymus medulla formation and central tolerance are restored in IKKalpha-/- mice that express an IKKalpha transgene in keratin 5 + thymic epithelial cells. J Immunol 2007, 178:829-837.
42. Ramirez A, Bravo A, Jorcano J L, Vidal M. Sequences 5′ of the bovine keratin 5 gene direct tissue- and cell-type-specific expression of a lacZ gene in the adult and during development. Differentiation 1994, 58:53-64.
43. Rothenberg E V, Moore J E, Yui M A. Launching the T-cell-lineage developmental programme. Nat Rev Immunol 2008, 8:9-21.
44. Sakaguchi S, Ono M, Setoguchi R. Foxp3 + CD25 + CD4 + natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev 2006, 212:8-27.
45. Sakaguchi S, Powrie F. Emerging challenges in regulatory T cell function and biology. Science 2007, 317:627-629.
46. Sakaguchi S, Setoguchi R, Yagi H, Nomura T. Naturally arising Foxp3-expressing CD25 + CD4 + regulatory T cells in self-tolerance and autoimmune disease. Curr Top Microbiol Immunol 2006, 305:51-66.
47. Hong K, Chu A, Ludviksson B R, Berg E L, Ehrhardt R O. IL-12, independently of IFN-gamma, plays a crucial role in the pathogenesis of a murine psoriasis-like skin disorder. J Immunol 1999, 162:7480-7491.
48. Ma H L, Liang S, Li J. IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation. J Clin Invest 2008, 118:597-607.
49. Schön M P, Detmar M, Parker C M. Murine psoriasis-like disorder induced by naive CD4 + T cells. Nat Med 1997, 3:183-188.
50. Sugiyama H, Gyulai R, Toichi E. Dysfunctional blood and target tissue CD4 + CD25high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation. J Immunol 2005, 174:164-173.
51. Tacke M, Hanke G, Hanke T, Hünig T. CD28-mediated induction of proliferation in resting T cells in vitro and in vivo without engagement of the T cell receptor: evidence for functionally distinct forms of CD28. Eur J Immunol 1997, 27:239-247.
52. Gogishvili T, Langenhorst D, Lühder F. Rapid regulatory T-cell response prevents cytokine storm in CD28 superagonist treated mice. PLoS ONE 2009, 4:e4643.
53. Beyersdorf N, Ding X, Hünig T, Kerkau T. Superagonistic CD28 stimulation of allogeneic T cells protects from acute graft versus host disease. Blood 2009, [Epub ahead of print]: PMID: 19721011
54. Guilliams M, Bosschaerts T, Herin M. Experimental expansion of the regulatory T cell population increases resistance to African trypanosomiasis. J Infect Dis 2008, 198:781-791.
55. Beyersdorf N, Gaupp S, Balbach K. Selective targeting of regulatory T cells with CD28 superagonists allows effective therapy of experimental autoimmune encephalomyelitis. J Exp Med 2005, 202:445-455.
56. Chan T, Ghahary A, Demare J. Development, characterization, and wound healing of the keratin 14 promoted transforming growth factor-beta1 transgenic mouse. Wound Repair Regen 2002, 10:177-187.
57. Gardembas-Pain M, Ifrah N, Foussard C, Boasson M, Saint Andre J P, Verret J L. Psoriasis after allogeneic bone marrow transplantation. Arch Dermatol 1990, 126:1523.
58. Stratis A, Pasparakis M, Rupec R A. Pathogenic role for skin macrophages in a mouse model of keratinocyte-induced psoriasis-like skin inflammation. J Clin Invest 2006, 116:2094-2104.
59. Wang H, Peters T, Kess D. Activated macrophages are essential in a murine model for T cell-mediated chronic psoriasiform skin inflammation. J Clin Invest 2006, 116:2105-2114.
60. Ghoreschi K, Weigert C, Röcken M. Immunopathogenesis and role of T cells in psoriasis. Clin Dermatol 2007, 25:574-580.